Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 , an investigational delta-like ligand 3 targeting T-cell engager
.
Merck announced today that it has completed the acquisition of Harpoon Therapeutics. The company will become a wholly-owned subsidiary of Merck, and Harpoon s common shares will no longer be publicly.
Merck closes $650M Harpoon acquisition njbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from njbiz.com Daily Mail and Mail on Sunday newspapers.
The sBLA is supported by data from the phase 3 NRG-GY018 trial, which included patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either pMMR or dMMR.